TN16 Long-Term Investigative Follow Up in TrialNet
Eligibility Form

Site Number:
Date of Visit:
Person Completing Form:

Participant ID:
Participant Letters:

1. Select the TrialNet Study in which the subject last participated *

○ TN01 Natural History (Pathway to Prevention)
○ TN05 Anti-CD20 (Rituximab)
○ TN06 NIP Pilot Diabetes Study
○ TN07 Oral Insulin
○ TN08 GAD New Onset
○ TN09 CTLA-4Ig (Abatacept)
○ TN10 Anti-CD3 (Teplizumab)
○ TN12 Metabolic Outcomes
○ TN14 Anti-IL1 (Canakinumab)
○ TN18 Abatacept Prevention
○ TN19 ATG-GCSF New Onset

2. Subject or Authorized Legal Representative has signed written informed consent/assent, as applicable. *

○ Y ○ N

If yes, date consent/assent was obtained: *

__ __ / __ __ __ / __ __ __ __
DAY MONTH YEAR

Is subject willing to allow TrialNet to put any remaining blood samples in the NIDDK repository? *

○ Y ○ N

3. Date of Diagnosis *

__ __ / __ __ __ / __ __ __ __
DAY MONTH YEAR